ESMO 2025 – Incyte impresses in KRAS G12D
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
ESMO 2025 – no starring role for Exelixis’s Cabometyx follow-on
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
ESMO 2025 – Boehringer and Bayer eye the front line
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
ESMO 2025 – Lilly strengthens Verzenio’s case
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
Incyte goes pivotal in CDK2
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
Boehringer goes earlier than Bayer
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
